Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHEAD 3-45 Study of lecanemab in preclinical Alzheimer's disease
2024-510888-39-00Phase 3Authorised
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of lecanemab in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Planned start Jul 2021; status: authorised.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-510888-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510888-39-00.